Bicycle Therapeutics PLCNASDAQ:BCYC
- LAST PRICE22.3600
- TODAY'S CHANGE (%)0.5100 (2.3341%)
- Bid / Lots21.8000/ 1
- Ask / Lots26.8900/ 1
- Open / Previous Close22.1000 / 21.8500
- Day Range
- 52 Week Range
- Volume386,468
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCYC |
|---|---|---|
| 09:32 ET | 608 | 22.1 |
| 09:34 ET | 400 | 22.5 |
| 09:36 ET | 200 | 22.7 |
| 09:38 ET | 300 | 22.94 |
| 09:39 ET | 697 | 23.07 |
| 09:41 ET | 603 | 22.96 |
| 09:43 ET | 200 | 22.96 |
| 09:45 ET | 300 | 22.81 |
| 09:48 ET | 100 | 22.81 |
| 09:50 ET | 300 | 22.48 |
| 09:52 ET | 900 | 22.5499 |
| 09:54 ET | 7046 | 22.5084 |
| 09:56 ET | 2104 | 22.62 |
| 09:57 ET | 7786 | 22.685 |
| 09:59 ET | 100 | 22.799 |
| 10:03 ET | 5159 | 22.65 |
| 10:08 ET | 200 | 22.67 |
| 10:10 ET | 3100 | 22.64 |
| 10:12 ET | 2600 | 22.355 |
| 10:15 ET | 600 | 22.255 |
| 10:17 ET | 200 | 22.255 |
| 10:21 ET | 239 | 22.35 |
| 10:24 ET | 100 | 22.35 |
| 10:26 ET | 300 | 22.385 |
| 10:32 ET | 2970 | 22.2 |
| 10:37 ET | 1061 | 22.27 |
| 10:39 ET | 200 | 22.195 |
| 10:46 ET | 100 | 22.2 |
| 10:50 ET | 400 | 22.28 |
| 10:51 ET | 3223 | 22.21 |
| 10:53 ET | 9328 | 22.27 |
| 10:55 ET | 1100 | 22.255 |
| 10:57 ET | 500 | 22.27 |
| 11:02 ET | 2040 | 22.25 |
| 11:06 ET | 1475 | 22.25 |
| 11:08 ET | 280 | 22.23 |
| 11:09 ET | 1599 | 22.21 |
| 11:18 ET | 152 | 22.25 |
| 11:20 ET | 100 | 22.2197 |
| 11:24 ET | 200 | 22.22 |
| 11:26 ET | 100 | 22.25 |
| 11:29 ET | 2022 | 22.26 |
| 11:33 ET | 100 | 22.29 |
| 11:36 ET | 100 | 22.255 |
| 11:40 ET | 108 | 22.255 |
| 11:47 ET | 200 | 22.21 |
| 11:51 ET | 300 | 22.255 |
| 11:54 ET | 300 | 22.255 |
| 11:56 ET | 1200 | 22.26 |
| 11:58 ET | 100 | 22.26 |
| 12:02 ET | 600 | 22.25 |
| 12:05 ET | 200 | 22.2 |
| 12:07 ET | 500 | 22.2125 |
| 12:12 ET | 700 | 22.1637 |
| 12:14 ET | 1601 | 22.16 |
| 12:16 ET | 6009 | 22.06 |
| 12:18 ET | 656 | 22.125 |
| 12:20 ET | 1611 | 22.2 |
| 12:21 ET | 480 | 22.215 |
| 12:25 ET | 600 | 22.2075 |
| 12:27 ET | 100 | 22.19 |
| 12:30 ET | 207 | 22.19 |
| 12:32 ET | 400 | 22.13 |
| 12:34 ET | 100 | 22.165 |
| 12:36 ET | 100 | 22.2 |
| 12:39 ET | 312 | 22.15 |
| 12:41 ET | 900 | 22.155 |
| 12:43 ET | 1500 | 22.085 |
| 12:50 ET | 100 | 22.105 |
| 12:52 ET | 100 | 22.105 |
| 12:57 ET | 200 | 22.105 |
| 12:59 ET | 4678 | 22.17 |
| 01:08 ET | 100 | 22.15 |
| 01:10 ET | 1625 | 22.11 |
| 01:17 ET | 625 | 22.14 |
| 01:28 ET | 200 | 22.13 |
| 01:30 ET | 900 | 22.101 |
| 01:35 ET | 100 | 22.1 |
| 01:44 ET | 1206 | 22.13 |
| 01:48 ET | 1425 | 22.12 |
| 01:50 ET | 400 | 22.1 |
| 01:53 ET | 200 | 22.13 |
| 01:55 ET | 500 | 22.13 |
| 02:00 ET | 644 | 22.1 |
| 02:02 ET | 300 | 22.1 |
| 02:06 ET | 15201 | 22.13 |
| 02:08 ET | 8234 | 22.09 |
| 02:09 ET | 200 | 22.03 |
| 02:11 ET | 200 | 22.01 |
| 02:15 ET | 100 | 22.01 |
| 02:18 ET | 300 | 22.07 |
| 02:22 ET | 100 | 22.08 |
| 02:24 ET | 100 | 22.04 |
| 02:26 ET | 100 | 22.085 |
| 02:27 ET | 105 | 22.085 |
| 02:29 ET | 100 | 22.085 |
| 02:31 ET | 800 | 22.04 |
| 02:36 ET | 100 | 22.01 |
| 02:45 ET | 100 | 22.055 |
| 02:49 ET | 300 | 22.02 |
| 02:54 ET | 200 | 22.055 |
| 02:56 ET | 200 | 22.04 |
| 03:00 ET | 100 | 22.02 |
| 03:05 ET | 450 | 22.06 |
| 03:07 ET | 200 | 22.02 |
| 03:09 ET | 1104 | 22.01 |
| 03:18 ET | 4440 | 22 |
| 03:20 ET | 2709 | 22 |
| 03:21 ET | 5610 | 22.05 |
| 03:25 ET | 100 | 22.075 |
| 03:27 ET | 100 | 22.06 |
| 03:30 ET | 250 | 22.05 |
| 03:36 ET | 4330 | 22.11 |
| 03:38 ET | 100 | 22.12 |
| 03:39 ET | 5500 | 22.07 |
| 03:41 ET | 800 | 22.1 |
| 03:43 ET | 2550 | 22.12 |
| 03:48 ET | 100 | 22.11 |
| 03:50 ET | 4737 | 22.2 |
| 03:52 ET | 100 | 22.19 |
| 03:54 ET | 1000 | 22.2144 |
| 03:56 ET | 2742 | 22.21 |
| 03:57 ET | 5350 | 22.29 |
| 03:59 ET | 8566 | 22.36 |
May 3, 2024
DJ Bicycle Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 3:29PM ET on Friday May 03, 2024 by Dow Jones
3:29PM ET on Friday May 03, 2024 by Dow Jones
May 2, 2024
*DJ Bicycle Therapeutics 1Q Loss/Shr 62c >BCYC, from 7:00AM ET on Thursday May 02, 2024 by Dow Jones
7:00AM ET on Thursday May 02, 2024 by Dow JonesBicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results, from 7:00AM ET on Thursday May 02, 2024 by Dow Jones
7:00AM ET on Thursday May 02, 2024 by Dow Jones
Apr 24, 2024
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting, from 10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bicycle Therapeutics PLC | 934.7M | -5.0x | --- |
Relay Therapeutics Inc | 844.2M | -2.6x | --- |
Immunome Inc | 882.4M | -4.4x | --- |
Viridian Therapeutics Inc | 936.3M | -3.2x | --- |
Exscientia PLC | 629.3M | -3.5x | --- |
Tango Therapeutics Inc | 811.2M | -7.0x | --- |
Company Information
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Contact Information
- Headquarters
- Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
- Phone
- 122-326-1503
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Pierre Legault
- Chief Executive Officer, Executive Director
- Kevin Lee
- Chief Financial Officer, Principal Financial Officer
- Alethia Young
- Chief Operating Officer
- Alistair Milnes
- Chief Technology Officer
- Michael Skynner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $934.7M |
|---|---|
Revenue (TTM) | $41.6M |
Shares Outstanding | 42.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-4.45 |
Book Value | $8.74 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | 22.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -432.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
